Top Line:
The Study: HYPO-RT-PC was one of the first randomized trials to report on outcomes for ultrahypofractionated radiation for prostate cancer. Recall that 1200 men ≤75 years with intermediate- (majority) or high-risk localized prostate cancer (no ADT allowed) were randomized to conventional fractionation (78 Gy in 39 fx over 8 weeks) versus ultra-hypofractionation (42.7 Gy in 7 fx over 2.5 weeks). The 5-year data showed non-inferior failure-free survival (FFS) with similar late toxicity, albeit with more acute GU toxicity in the ultra-hypo arm. Now, with median follow-up beyond 10 years, the curves have matured—and subtly diverged. Ten-year FFS was 65% with conventional RT versus 72% with ultra-hypo (adjusted HR 0.84, 95% CI 0.69–1.03), confirming non-inferiority. A post-hoc fixed timepoint analysis favored ultra-hypofractionation (p=0.025), though superiority was not formally met. Distant metastases (9% vs 8%), prostate cancer–specific mortality (4% vs 4%), and overall survival (79% vs 81%) were similar. Intriguingly, subgroup analysis suggested a signal favoring ultra-hypo in high-risk patients (interaction p=0.045), hypothesis-generating at best. Late grade ≥2 GU toxicity at 10 years was 30% vs 28%; GI toxicity 14% vs 14%. Grade ≥3 events remained low (GU 7% both arms; GI 2% both). No late safety surprises emerged.
TBL: The 10-year data solidify seven-fraction RT as a durable, safe standard—particularly for intermediate-risk disease—without ADT. If anything, time appears to favor ultra-hypo. Less may indeed be more… and faster. | Nilsson, Lancet Oncol 2026
The Study: HYPO-RT-PC was one of the first randomized trials to report on outcomes for ultrahypofractionated radiation for prostate cancer. Recall that 1200 men ≤75 years with intermediate- (majority) or high-risk localized prostate cancer (no ADT allowed) were randomized to conventional fractionation (78 Gy in 39 fx over 8 weeks) versus ultra-hypofractionation (42.7 Gy in 7 fx over 2.5 weeks). The 5-year data showed non-inferior failure-free survival (FFS) with similar late toxicity, albeit with more acute GU toxicity in the ultra-hypo arm. Now, with median follow-up beyond 10 years, the curves have matured—and subtly diverged. Ten-year FFS was 65% with conventional RT versus 72% with ultra-hypo (adjusted HR 0.84, 95% CI 0.69–1.03), confirming non-inferiority. A post-hoc fixed timepoint analysis favored ultra-hypofractionation (p=0.025), though superiority was not formally met. Distant metastases (9% vs 8%), prostate cancer–specific mortality (4% vs 4%), and overall survival (79% vs 81%) were similar. Intriguingly, subgroup analysis suggested a signal favoring ultra-hypo in high-risk patients (interaction p=0.045), hypothesis-generating at best. Late grade ≥2 GU toxicity at 10 years was 30% vs 28%; GI toxicity 14% vs 14%. Grade ≥3 events remained low (GU 7% both arms; GI 2% both). No late safety surprises emerged.
TBL: The 10-year data solidify seven-fraction RT as a durable, safe standard—particularly for intermediate-risk disease—without ADT. If anything, time appears to favor ultra-hypo. Less may indeed be more… and faster. | Nilsson, Lancet Oncol 2026